Bioelectronic Medicine is a new field of medicine that
combines neuroscience, molecular biology and bioengineering to delve into the
nervous system to treat disease and injury without the use of drugs. Bioelectronic
Medicine promises to bring new insights into the diagnosis and treatment of
diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory
bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding,
ischemia, organ transplantation, cardiovascular disease, neurodegenerative diseases,
and others.
Bioelectronics is a relatively new branch of healthcare,
which, as the name suggests, focuses on the nexus of electronics and biological
research. The term can encompass a number of different therapies, but BioSig’s
main focus is on creating develop and deliver the advanced signal processing
solutions that will unlock the future of bioelectronic medicine, starting with
the PURE EP™ System. Namely, this Westport-based medical device company is developing
a proprietary biomedical signal-processing platform designed to address an
unmet technology need for the electrophysiology (EP) marketplace.
“Bioelectronic medicine has the potential to transform
healthcare throughout the coming decades, much like we’ve seen with the biotech
revolution. But the first order of business for those active in the field is to
develop a collective vision for how these technologies can improve lives – a
vision that other stakeholders can understand and act on,” says Ken Londoner,
founder, CEO, and chairman, BioSig Technologies. Since its founding in 2009,
BioSig Technologies has been working hard to lead one of the most innovative
and most promising frontiers in healthcare. In order to achieve that, BioSig is
now ready to commercialize the company’s first product: the PURE EP™ System. Looking
further ahead, BioSig expects to publish trial results, grow internationally,
and expand their product pipeline.
In 2018, BioSig received FDA 510(k) clearance for PURE EP™,
began market launch, and BioSig was uplisted to the NASDAQ national exchange. BioSig
Technologies (BSGM) has a market capitalization of $82.52M. Recently BSGM
recorded volume of 210046 shares in most recent trading session as compared to
an average volume of 185.63K shares. It shows that the shares were traded in
the recent trading session and traders shown interest in BSGM stock.
No comments:
Post a Comment